menu
    • menu
    [{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Norethisterone","moa":"||LH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Relugolix","moa":"||Gonadotropin-releasing hormone receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Alexion Pharmaceuticals | Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Danicopan","moa":"||Complement factor D","graph1":"Undisclosed","graph2":"Phase I","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals | Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals | Celerion"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BMS-986166","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMS-986322","moa":"||TYK2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMS-986196","moa":"||BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Ethinylestradiol","moa":"||Human immunodeficiency virus Integrase (HIV IN)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ViiV Healthcare \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Norethindrone (Norethisterone)

    Menu

    Norethindrone (Norethisterone)

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ViiV Healthcare

                            United Kingdom arrow
                            EPSC
                            Not Confirmed

                            ViiV Healthcare

                            United Kingdom arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VH4524184,Ethinyl Estradiol,Norethisterone

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin)...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 15, 2024

                            Lead Product(s) : VH4524184,Ethinyl Estradiol,Norethisterone

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aurobindo Pharma Limited

                            India arrow
                            EPSC
                            Not Confirmed

                            Aurobindo Pharma Limited

                            India arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Norethisterone,Inapplicable

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aurobindo Receives FDA Approval for Emzahh (Norethindrone Tablets USP), 0.35mg

                            Details : Norethisterone acts similarly to endogenous progesterone with a much higher potency, it acts at the pelvic level to alter cervical and endometrial function, as well as via the inhibition of pituitary hormones that play a role in follicular maturation and...

                            Product Name : Emzahh-Generic

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            October 01, 2023

                            Lead Product(s) : Norethisterone,Inapplicable

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bristol Myers Squibb

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Bristol Myers Squibb

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BMS-986196,Ethinyl Estradiol,Norethisterone

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Drug-drug Interaction of BMS-986196 With Oral Contraceptives in Healthy Female Partici...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 06, 2023

                            Lead Product(s) : BMS-986196,Ethinyl Estradiol,Norethisterone

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bristol Myers Squibb

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Bristol Myers Squibb

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BMS-986322,Ethinyl Estradiol,Norethisterone

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estra...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 14, 2022

                            Lead Product(s) : BMS-986322,Ethinyl Estradiol,Norethisterone

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Bristol Myers Squibb

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Bristol Myers Squibb

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BMS-986166,Ethinyl Estradiol,Norethisterone

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Characterize the Drug Levels of an Oral Contraceptive With and Without BMS-986166 in Healthy Female...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 22, 2021

                            Lead Product(s) : BMS-986166,Ethinyl Estradiol,Norethisterone

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Myovant Sciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Myovant Sciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Relugolix,Estradiol,Norethisterone,Erythromycin

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in H...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 19, 2021

                            Lead Product(s) : Relugolix,Estradiol,Norethisterone,Erythromycin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Alexion Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Alexion Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Danicopan,Warfarin Sodium,Bupropion Hydrochloride,Ethinyl Estradiol,Norethisterone

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Alexion Pharmaceuticals | Celerion

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Drug Interaction Study of Danicopan

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 14, 2021

                            Lead Product(s) : Danicopan,Warfarin Sodium,Bupropion Hydrochloride,Ethinyl Estradiol,Norethisterone

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Alexion Pharmaceuticals | Celerion

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            University of Sao Paulo

                            Country arrow
                            EPSC
                            Not Confirmed

                            University of Sao Paulo

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Norethisterone,Inapplicable

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase IV

                            Sponsor : Organon

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treatment of Prolonged Uterine Bleeding of Etonogestrel (ENG)-Releasing Implant

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            August 07, 2019

                            Lead Product(s) : Norethisterone,Inapplicable

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase IV

                            Sponsor : Organon

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Bristol Myers Squibb

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Bristol Myers Squibb

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BMS-986256,Ethinyl Estradiol,Norethisterone

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participa...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 11, 2019

                            Lead Product(s) : BMS-986256,Ethinyl Estradiol,Norethisterone

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Eisai Inc

                            U.S.A arrow
                            EPSC
                            Not Confirmed